Long-term survival in chronic myelocytic leukemia after a first primary malignancy

Leukemia Research

Volumn 33, Issue 12, 2009, Pages 1604-1608

  Brenner, Hermann ^a   Gondos, Adam ^a   Pulte, Dianne ^a,b  

^a GERMAN CANCER RESEARCH CENTER DKFZ   (Germany)

^b WEILL CORNELL MEDICAL CENTER   (United States)

Author keywords

Cancer registries; Chronic myelocytic leukemia; Neoplasm; Survival

Indexed keywords

ADOLESCENT; ADULT; AGE DISTRIBUTION; AGED; ARTICLE; CANCER SURVIVAL; CHRONIC MYELOID LEUKEMIA; FEMALE; HUMAN; MAJOR CLINICAL STUDY; MALE; PRIMARY TUMOR; PRIORITY JOURNAL; PROGNOSIS; SURVIVAL RATE; SURVIVAL TIME; TREND STUDY; UNITED STATES;

ADOLESCENT; ADULT; AGED; HUMANS; LEUKEMIA, MYELOGENOUS, CHRONIC, BCR-ABL POSITIVE; MIDDLE AGED; NEOPLASMS, SECOND PRIMARY; SURVIVAL ANALYSIS; YOUNG ADULT;

EID: 70249093265     PISSN: 01452126     EISSN: None     Source Type: Journal    
DOI: 10.1016/j.leukres.2009.01.042     Document Type: Article

References (31)

1. Aguiar R.C. Therapy-related chronic myeloid leukemia: an epidemiological, clinical and pathogenetic appraisal. Leuk Lymphoma 29 (1998) 17-26
2. Nandakumar A., Davis S., Moolgavkar S., Witherspoon R.P., and Schwartz S.M. Myeloid leukaemia following therapy for a first primary cancer. Br J Cancer 63 (1991) 782-788
3. Howard R.A., Gilbert E.S., Chen B.E., Hall P., Storm H., Pukkala E., et al. Leukemia following breast cancer: an international population-based study of 376,825 women. Breast Cancer Res Treat 105 (2007) 359-368
4. Shimon I., Kneller A., and Olchovsky D. Chronic myeloid leukaemia following 131I treatment for thyroid carcinoma: a report of two cases and review of the literature. Clin Endocrinol (Oxf) 43 (1995) 651-654
5. Moloney W.C. Radiogenic leukemia revisited. Blood 70 (1987) 905-908
6. Larson R.A. Is secondary leukemia an independent poor prognostic factor in acute myeloid leukemia?. Best Pract Res Clin Haematol 20 (2007) 29-37
7. Cohen M.H., Williams G., Johnson J.R., Duan J., Gobburu J., Rahman A., et al. Approval summary for imatinib mesylate capsules in the treatment of chronic myelogenous leukemia. Clin Cancer Res 8 (2002) 935-942
8. Druker B.J., Guilhot F., O'Brien S.G., Gathmann I., Kantarjian H., Gattermann N., et al. Five-year follow-up of patients receiving imatinib for chronic myeloid leukemia. N Engl J Med 355 (2006) 2408-2417
9. Kantarjian H., Sawyers C., Hochhaus A., Guilhot F., Schiffer C., Gambacorti-Passerini C., et al. Hematologic and cytogenetic responses to imatinib mesylate in chronic myelogenous leukemia. N Engl J Med 346 (2002) 645-652
10. Surveillance, Epidemiology, and End Results (SEER) Program (www.seer.cancer.gov) Limited-Use Data (1973-2004), National Cancer Institute, DCCPS, Surveillance Research Program, Cancer Statistics Branch, released April 2007, based on the November 2006 submission.
11. Brenner H., Gefeller O., and Hakulinen T. Period analysis for 'up-to-date' cancer survival data: theory, empirical evaluation, computational realisation and applications. Eur J Cancer 40 (2004) 326-335
12. Brenner H., and Hakulinen T. Up-to-date and precise estimates of cancer patient survival: model-based period analysis. Am J Epidemiol 164 (2006) 689-696
13. Brenner H., and Gefeller O. An alternative approach to monitoring cancer patient survival. Cancer 78 (1996) 2004-2010
14. Brenner H., and Hakulinen T. Up-to-date long-term survival curves of patients with cancer by period analysis. J Clin Oncol 20 (2002) 826-832
15. Brenner H., Soderman B., and Hakulinen T. Use of period analysis for providing more up-to-date estimates of long-term survival rates: empirical evaluation among 370,000 cancer patients in Finland. Int J Epidemiol 31 (2002) 456-462
16. Ederer F., Axtell L.M., and Cutler S.J. The relative survival rate: a statistical methodology. Natl Cancer Inst Monogr 6 (1961) 101-121
17. Henson D.E., and Ries L.A. The relative survival rate. Cancer 76 (1995) 1687-1688
18. Ederer F, Heise H. Instructions to IBM 650 programmers in processing survival computations. Methodological note No. 10. Bethesda, MD: National Cancer Institute; 1959.
19. Arias E. United States life tables, 2000. vol. 51: Natl Vit Stat Rep;2002:1-39.
20. Guilhot F., Apperley J., Kim D.W., Bullorsky E.O., Baccarini M., Roboz G.J., et al. Dasatinib induces significant hematologic and cytogenetic responses in patients with imatinib-resistant or -intolerant chronic myeloid leukemia in accelerated phase. Blood 109 (2007) 4143-4150
21. Kantarjian H., Talpaz M., O'Brien S., Giles F., Faderl S., Verstovsek S., et al. Survival benefit with imatinib mesylate therapy in patients with accelerated-phase chronic myelogenous leukaemia-comparison with historic experience. Cancer 103 (2005) 2099-2108
22. Kantarjian H.M., Cortes J.E., O'Brien S., Luthra R., Giles F., Verstovsek S., et al. Long-term survival benefit and improved complete cytogenetic and molecular response rates with imatinib mesylate in Philadelphia chromosome-positive chronic-phase chronic myeloid leukemia after failure of interferon-alpha. Blood 104 (2004) 1979-1988
23. Kantarjian H.M., Talpaz M., O'Brien S., Jones D., Giles F., Garcia-Manero G., et al. Survival benefit with imatinib mesylate versus interferon-alpha-based regimens in newly diagnosed chronic-phase chronic myelogenous leukemia. Blood 108 (2006) 1835-1840
24. Ramanarayanan J., Dunford L.M., Baer M.R., Sait S.N., Lawrence W., and McCarthy P.L. Chronic myeloid leukemia after treatment of lymphoid malignancies: response to imatinib mesylate and favorable outcomes in three patients. Leuk Res 30 (2006) 701-705
25. Nilsson B., Sjolund K., Kindblom L.G., Meis-Kindblom J.M., Bumming P., Nilsson O., et al. Adjuvant imatinib treatment improves recurrence-free survival in patients with high-risk gastrointestinal stromal tumours (GIST). Br J Cancer 96 (2007) 1656-1658
26. Bajaj G.K., Zhang Z., Garrett-Mayer E., Drew R., Sinibaldi V., Pili R., et al. Phase II study of imatinib mesylate in patients with prostate cancer with evidence of biochemical relapse after definitive radical retropubic prostatectomy or radiotherapy. Urology 69 (2007) 526-531
27. Lin A.M., Rini B.I., Weinberg V., Fong K., Ryan C.J., Rosenberg J.E., et al. A phase II trial of imatinib mesylate in patients with biochemical relapse of prostate cancer after definitive local therapy. BJU Int 98 (2006) 763-769
28. Modi S., Seidman A.D., Dickler M., Moasser M., D'Andrea G., Moynahan M.E., et al. A phase II trial of imatinib mesylate monotherapy in patients with metastatic breast cancer. Breast Cancer Res Treat 90 (2005) 157-163
29. Rocha A., Azevedo I., and Soares R. Progesterone sensitizes breast cancer MCF7 cells to imatinib inhibitory effects. J Cell Biochem 103 (2008) 607-614
30. Taja-Chayeb L., Chavez-Blanco A., Martinez-Tlahuel J., Gonzales-Fierro A., Candelaria M., et al. Expression of platelet derived growth factor family members and the potential role of imatinib mesylate for cervical cancer. Cancer Cell Int 6 (2006) 22
31. Itsukuma T., Ishikawa H., Misawa M., Fujimori Y., Nakagawa K., Hirota S., et al. Familial adenomatous polyposis complicated by chronic myelogenous leukemia: response to imatinib mesylate. J Gastroenterol 42 (2007) 402-405